EP1289457A1 - Wound dressing - Google Patents
Wound dressingInfo
- Publication number
- EP1289457A1 EP1289457A1 EP01955296A EP01955296A EP1289457A1 EP 1289457 A1 EP1289457 A1 EP 1289457A1 EP 01955296 A EP01955296 A EP 01955296A EP 01955296 A EP01955296 A EP 01955296A EP 1289457 A1 EP1289457 A1 EP 1289457A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- film
- dressing
- wound
- particles
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims abstract description 35
- 239000002245 particle Substances 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 230000035699 permeability Effects 0.000 claims abstract description 11
- 229920003043 Cellulose fiber Polymers 0.000 claims abstract description 10
- 239000002023 wood Substances 0.000 claims abstract description 10
- 230000003746 surface roughness Effects 0.000 claims abstract description 7
- 244000005700 microbiome Species 0.000 claims abstract description 5
- 230000008093 supporting effect Effects 0.000 claims abstract description 5
- 229920002678 cellulose Polymers 0.000 claims description 51
- 239000001913 cellulose Substances 0.000 claims description 51
- 239000000463 material Substances 0.000 claims description 18
- 239000012530 fluid Substances 0.000 claims description 17
- 239000011236 particulate material Substances 0.000 claims description 13
- 239000004627 regenerated cellulose Substances 0.000 claims description 8
- 230000005540 biological transmission Effects 0.000 claims description 4
- 238000013048 microbiological method Methods 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 230000002906 microbiologic effect Effects 0.000 abstract description 4
- 239000011148 porous material Substances 0.000 abstract description 2
- 230000001172 regenerating effect Effects 0.000 abstract description 2
- 239000010408 film Substances 0.000 description 162
- 208000027418 Wounds and injury Diseases 0.000 description 109
- 206010052428 Wound Diseases 0.000 description 106
- 210000003491 skin Anatomy 0.000 description 39
- 239000000835 fiber Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 229920000297 Rayon Polymers 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 210000000416 exudates and transudate Anatomy 0.000 description 10
- -1 gauze Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 229920002635 polyurethane Polymers 0.000 description 5
- 239000004814 polyurethane Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 229920001340 Microbial cellulose Polymers 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 210000001691 amnion Anatomy 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
- 208000012260 Accidental injury Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229920001131 Pulp (paper) Polymers 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229920006268 silicone film Polymers 0.000 description 2
- BSWGGJHLVUUXTL-UHFFFAOYSA-N silver zinc Chemical compound [Zn].[Ag] BSWGGJHLVUUXTL-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000012991 xanthate Substances 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- ZXGQAYORUOYCDO-BPLSWDSYSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;[(3r,5s,6s,7r,8s,9r,12r,13s,14s,15r)-6-[(2s,3r,4s,6r)-3-acetyloxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-8-[(2r,4s,5s,6s)-5- Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O.O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C ZXGQAYORUOYCDO-BPLSWDSYSA-N 0.000 description 1
- ZXSGQNYQJIUMQN-UHFFFAOYSA-N 3-(2-methylpiperidin-1-ium-1-yl)propyl benzoate;chloride Chemical compound Cl.CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 ZXSGQNYQJIUMQN-UHFFFAOYSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 244000235858 Acetobacter xylinum Species 0.000 description 1
- 235000002837 Acetobacter xylinum Nutrition 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960004008 butamben picrate Drugs 0.000 description 1
- ATAGSVCDFKGYPE-UHFFFAOYSA-N butamben picrate Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1.CCCCOC(=O)C1=CC=C(N)C=C1.OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ATAGSVCDFKGYPE-UHFFFAOYSA-N 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000003486 chemical etching Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940109357 desoxyribonuclease Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002649 leather substitute Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
- A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01012—Non-adhesive bandages or dressings characterised by the material being made of natural material, e.g. cellulose-, protein-, collagen-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01034—Non-adhesive bandages or dressings characterised by a property
- A61F13/01046—Air-vapor permeability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/06—Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings
- A61F13/064—Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings for feet
- A61F13/069—Decubitus ulcer bandages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00157—Wound bandages for burns or skin transplants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00182—Wound bandages with transparent part
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00246—Wound bandages in a special way pervious to air or vapours
- A61F2013/00263—Wound bandages in a special way pervious to air or vapours vapour permeability >500 g/m2/24h
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00246—Wound bandages in a special way pervious to air or vapours
- A61F2013/00268—Wound bandages in a special way pervious to air or vapours impervious, i.e. occlusive bandage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00348—Wound bandages lint-free, i.e. non-linting or frying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00519—Plasters use for treating burn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00655—Plasters adhesive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00855—Plasters pervious to air or vapours
- A61F2013/00876—Plasters pervious to air or vapours vapour permeability >500 g/mg/24h
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00855—Plasters pervious to air or vapours
- A61F2013/00885—Plasters pervious to air or vapours impervious, i.e. occlusive bandage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00897—Plasters package for individual plaster
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/0091—Plasters containing means with disinfecting or anaesthetics means, e.g. anti-mycrobic
Definitions
- the present invention relates to the field of cellulosic films which are optionally useful in the preparation of wound dressings.
- a wound can be considered any damage to the epidermis and/or dermis of the human or animal body however caused (for example any abscess, abrasion, blister, boil, blotch, burn, carbuncle, cosmetic affliction, cut, dermatological pathology, furuncle, graft donor site, incision, injury, lesion, pimple, pustule, skin graft [e.g. autogeneous, allogeneic and/or donor], sore, trauma, ulcer and/or wound).
- a wound may be caused by any external insult, disorder, disease, injury, surgery, treatment and/or underlying condition.
- the field of wound dressing relates to means for locating adjacent a wound on a human or animal body any device or composition (for example a cataplasm, cream, dressing, emulsion, film, granulate, gauze, liquid, medicament, patch, plaster, poultice, powder, protecting material and/or sheet) as part of a local, non-systemic, topical method for the diagnosis, prophylaxis, surgery, therapy and/or treatment of a wound.
- any device or composition for example a cataplasm, cream, dressing, emulsion, film, granulate, gauze, liquid, medicament, patch, plaster, poultice, powder, protecting material and/or sheet
- a material for protecting an externally wounded or burnt skin at an accident or disaster, to promoting regrowth of the epidermis and healing of the wound is also known as vulnerary cover, artificial skin and/or wound dressing.
- vulnerary cover, artificial skin and/or wound dressing A wide variety of products are currently available in the medical field for such uses.
- Nonresorbable gauze/sponge dressings for external use
- sterile or non-sterile devices intended for medical purposes, such as to be placed directly on a patient's wound to absorb exudate. They comprise a strip, piece or pad made from open woven or non-woven mesh cotton, cellulose or a simple chemical derivative of cellulose,
- Hydrophilic wound dressings Available in sterile or non-sterile form, hydrophilic wound dressings are intended to cover a wound and to absorb exudate.
- Occlusive dressings are non-resorbable, sterile or non-sterile devices intended to cover a wound, to provide or support a moist wound environment, and to allow the exchange of gases such as oxygen and water vapor through the device.
- Hydrogel wound and burn dressings These dressings, available in sterile or non-sterile form, are intended to cover a wound, to absorb wound exudate, to control bleeding or fluid loss, and to protect against abrasion, friction, desiccation and/or contamination. They comprise a non-resorbable matrix made of hydrophilic polymers and/or other material in combination with at least 50% water and are capable of absorbing exudate.
- Interactive wound and burn dressings are examples of synthetic polymeric material, such as polyurethane, with or without an adhesive backing.
- These products contain added drugs such as antimicrobial agents or added biologies such as growth factors and/or comprise materials derived from animal sources.
- Glycerol physiologically acceptable fluids
- Gauze pads impregnated with antibacterial agents may be used as wipes to clean and disinfect or otherwise treat skin areas.
- Wide-mesh gauze impregnated with hydrophobic ointments such as paraffin is widely used as a non-adherent dressing to cover large surface wounds.
- the gauze-type dressings are not without their disadvantages. For instance, frequent changes of such dressings are necessary in order to observe the healing process and to apply medication. Such changes are often accompanied by discomfort to the patient since some adherence to the wound or wound exudate normally occurs. Moreover, the gauze-type dressings do not protect the wound from extraneous bacteria nor do they control the proper moisture balance favourable to healing. Gauze is not lint-free and the deposition of lint on wound surfaces is considered undesirable.
- Autologous grafting in which skin is taken from another location on the patients body and heterogeneous grafting, which may be of two types.
- the first type is where either human skin from donors or cadavers, or amniotic membrane from donors may be used.
- the second type is where skin from pigs or bovine embryos, or artificial skins such as silicon, collagen, mixtures of collagen and silicon, or polytetrafluoroethylene polyurethane are used.
- Autologous grafting involves a surgical operation, extracting an area of the patients own skin from an selected donor region, to be immediately applied over the wound. Since this causes a trauma equivalent to a second degree burn, this is only justifiable in patients who have third degree burns.
- the first method of allogeneic grafting uses human skin from donors, and this method is extremely rarely used since as well as requiring donors to submit themselves to extensive traumas, the benefits of this type of grafting are transitory as the graft only lasts for a maximum of two weeks.
- Grafting human skin from cadavers is almost never used, due to the inherent difficulties in obtaining cadavers at the appropriate time, together with their entire medical histories. There also exist ethical and legal difficulties, as well as objections from the family of the deceased.
- Use of an amniotic membrane requires a careful choice of donor, and the total absence of risk of contamination. The membrane must be prepared by a specialised team in a medical centre, and must be done within twelve hours. Like artificial skin substitutes, amniotic membranes are not durable lasting no more than a week.
- pigskin can give good results as with the correct preparation can give this skin anatomic characteristics similar to human skin.
- LPS lyophilised pig skin
- LPS is soft and has a good adhesion to a wound and is superior in that it promotes regrowth of the skin.
- the care required in the choice of animal and the preparation of a piece of skin make this option extremely laborious and complex.
- pigskin must be stored under refrigeration (maximum temperature 4°C) in physiological serum with antibiotics. This skin once applied to the patient has a limited durability of two weeks.
- the second type of synthetic film is of an organic material prepared from derivatives of animal blood such as for example collagen and is prepared from two integral layers (for example a non-woven fabric or film comprising collagen complexed with a silicone film).
- Such films have no antigenic properties and can be sterilised.
- the layer which enters into contact with the lesion is formed from dried organic material (preferably derived from animal blood, in which case the film has excellent absorbing properties and is not irritating to the human body, but since the starting material is expensive, such film is not easily available).
- the other layer is silicon, polyurethane, or the like and functions as a support, this layer being exposed. The organic part is absorbed by the organism, and the support is then rejected.
- polyvinyl alcohol, gelatin, and a wide variety of polymeric materials have been disclosed in the literature as being useful in the treatment of accidental and surgical wounds.
- a complex of a polyamino acid film and a synthetic polymer film has been proposed as a wound dressing.
- Such films are not decomposed by protease, they must be supported by an appropriate support such as a silicone film and thus the manufacturing process is complicated.
- Hydrophilic polymer gels of polyethylene oxide and their use as wound dressings are described in U.S. 3,419,006 and suggested to be particularly useful in the treatment of bums, surgical and accidental injuries to the skin and eyes, and in a variety of dermatological applications. These gel dressings are alleged to provide a barrier to bacteria and viruses, to be permeable to vapors and gases while being impermeable to fluids, and to control the moisture environment of the wound.
- Dr Vartak et aj describes the use of conventional untreated regenerated plain cellulose film (Cellophane ®) as a dressing for burn graft donor sites.
- conventional cellulose film Cellophane ®
- Dr Vatak selected such plain cellulose film as much for its cheapness as for any optimal wound dressings properties.
- US 5,558,861 (assignee Ajinomoto Co., Inc.) describes a gel of microbially-produced cellulose, characterised in that the microbially-produced cellulose is modified by physically or chemically bonding an animal cell adhesive protein to the cellulose, and/or substituting hydrogen atoms of at least part of the hydroxyl groups of the cellulose with a positively or negatively charged organic group.
- This gel is used as a carrier for mass culture of animal cells or as a medical vulnerary cover.
- it is complicated and expensive to produce as it requires chemical treatment of a microbial cellulose film.
- the film thus prepared is suitable for use as an artificial skin graft, a separating membrane, or artificial leather. This produces the cellulose film by a microbiologic method.
- EP 0114481 describes liquid loaded pads useful as wound and burn dressings are prepared from pellicles of microbially-produced cellulose gel obtained, for example, by culturing Acetobacter xylinum.
- a pellicle having a thickness from about 0.1 to 15 mm or greater is processed to replace the culture medium with water or other physiologically compatible liquid.
- the liquid-loaded pellicle is sterilised prior to its use as a dressing or in other medical applications.
- These gel-like films have poor adhesion to epidermal cells, are readily peeled from the wound causing contamination, and do not promote regrowth of the skin. They are also porous to micro-organisms and so do not satisfactorily protect the wound from infection.
- microbially-produced cellulose denotes cellulose produced by a microbe.
- a microbial cellulose gel denotes a solid colloidal solution of microbially-produced cellulose in a physiologically-acceptable liquid such as deionised water, saline or glycerol.
- WO 00/05310 (University of Minnesota) describes a method of making edible films to pack food using as a raw material non-wood sources of cellulose fibers. Such films are formed from entangled micro-fibers of cellulose optionally dispersed within lipids and thus have a woven or entangled discontinuous structure of cellulose unlike a conventional cellulose sheet.
- JP 09-A-195194 (OJI Paper Ltd) describes a paper comprising 1 to 30 % by dry weight of non-wood pulp cellulose fibers used to make tea bags.
- the present invention resolves some or all of the problems described above with methods for wound dressing and devices for achieving the same, in a simple but effective way by providing a novel cellulosic film which optionally has improved wound dressing properties.
- a self supporting cellulosic film having two substantially parallel and opposed surfaces characterised in that the cellulosic film is made by a non microbiological method and has a wet flatness less than about 35 seconds.
- the film comprises at least one cellulose layer which is substantially continuous, more preferably non-woven and/or entangled, in structure.
- wet flatness is a measure of the absorption and dimensional stability i.e. wrinkleability of the film. Low wrinkleability leads to less blood pockets being formed and hence less pain.
- Wet flatness herein was measured in units of time (seconds) in the following quantitative "blue spot test" where 0.2 mis of a 0.1 % Methylene Blue dye solution in water was spotted onto a glass plate using a micro pipette. A 5cm square sample of film was placed centrally over the drop of dye solution. The time taken for the drop to be absorbed was measured, the faster the better.
- the wet flatness of the film is less than about 30 seconds, more preferably less than about 20 seconds, most preferably less than about 15 seconds.
- it may be desirable for the wet flatness absorption time not to be so rapid so there is insufficient time to position the dressing and correctly locate it adjacent the wound. However the most rapid absorption time possible may still be desirable for certain applications.
- the desired wet flatness may be achieved by any suitable means, which may for example suitably modify the physiochemical properties at the surface of the cellulose film.
- the cellulose film surface may be modified by suitable mechanical treatment, chemical treatment and/or additives.
- Suitable techniques may include embossing; printing; patterning, chemical etching, drawing the cellulose film web over a suitably prepared surface (e.g. a surface roughened and/or chemically etched roller); and/or incorporation of particulate materials such as fibers to the film surface.
- the preferred technique is incorporation of particles.
- the non-microbial cellulose of the present invention is cellulose regenerated from a cellulosic dispersion in a non-solvating fluid (such as but not limited to NMMO, LiCI / DMP, LiCI/DemAc).
- a non-solvating fluid such as but not limited to NMMO, LiCI / DMP, LiCI/DemAc.
- a cellulose in a solvating fluid is "viscose" which is sodium cellulose xanthate in caustic soda.
- Cellulose from a dispersion can be cast into film by regenerating the cellulose jn situ by a suitable treatment (e.g. addition of suitable reagent which for viscose can be dilute sulfuric acid) and optionally extruding the cellulose thus formed.
- suitable treatment e.g. addition of suitable reagent which for viscose can be dilute sulfuric acid
- Such cellulose is known herein as regenerated cellulose and preferred films of the present invention comprise
- More preferred films of the present invention substantially comprise cellulose from a wood source, most preferably at least 90% of the cellulosic material is from a wood source.
- the cellulose film of the present invention comprises particulate material: the particles being present in an amount of from about 0.5% to about 25 % by weight of the total film; the particles being substantially located on or substantially near at least one of the film surfaces; and the mean linear dimension of the particles along their longest axis is from about 5 microns to about 5 mm.
- optimal film properties may be achieved with an amount of the particulate material being from about 5% to about 20% by weight of the film, conveniently from about 10% to about 15% by weight, more conveniently from about 12% to about 15% by weight.
- the cellularosic film of the present invention further exhibits at least one of the following properties; has an average thickness of up to about 45 microns; has a water permeability of at least about 100 g/m 2 .d; has a selective permeability with a molecular weight cut off such that micro-organisms are substantially prevented from crossing the film, (preferably having a film-pore size of less than about 1 micron); has a wet flatness as measured by the blue spot test of from less than about 35 seconds; has a haze value of at least about 10%; has an average surface roughness of at least about 10ml min "1 ; has some kind of stiffness when dry and yet becomes pliable and/or elastic after uptake of water; has good mechanical stability in the dry state but also after wetting; has a water vapor transmission rate (denoted herein by WVTR) of at least about 1 ,500 g/m 2 .d; and/or has at least about a 5 fold higher WVTR value when wet than
- Water permeability herein may be measured in standard test ASTM E 96 at 38°C and 90% relative humidity (RH).
- the water permeability of the film is from about 200 to about 10,000 g/m 2 .d, more preferably from about 400 to about 2,000 g/m 2 .d, most preferably from about 600 to about 1 ,600 g/m 2 .d, and especially about 1 ,500 g/m 2 .d.
- the water vapor transmission rate (WVTR) of the films herein may be measured in standard test ASTM E 96 at 37°C and 30% relative humidity (RH) using the water method for the dry film and the inverted water method for the wet film.
- WVTR of the dry film is from about 2000 to about 4,000 g/m 2 .d, more preferably from about 2,500 to about 3,000 g /m 2 .d.
- the wet film may show from about 5 to about 15 fold, preferably from about 5 to about 8 fold higher WVTR than the same film when dry.
- the average surface roughness of the film herein was measured using a Bendtsen Gauge as described in the DIN EN 53108 method.
- the average surface roughness of the film is from about 10 to about 80 ml min "1 , more preferably from about 20 to about 70 ml min "1 , most preferably from about 30 to about 60 ml min "1 .
- the haze value of the films herein were measured using a spherical hazemeter as described in ASTM D 1003.
- the haze value of the film is from about 10% to about 100%, more preferably from about 20% to about 80%, most preferably from about 30% to about 70%.
- Oxygen permeability herein may be measured in standard test ASTM D 3985 at 23°C and 0 to 5% RH.
- the oxygen permeability of the film is from about 0.1 to about 30 cm 3 / m 2 .d.bar, more preferably from about 1 to about 20 cm 3 / m 2 .d.bar, most preferably from about 2 to about 10 cm 3 / m 2 .d.bar, and especially about 8 cm 3 / m 2 .d.bar.
- the film further includes a plasticiser, more preferably in an amount from about 10% to about 30%, most preferably about 20% by weight of the cellulose film.
- the plasticiser may be any suitable material which is compatible with wound dressings for example substantially non-toxic in the amounts used.
- the plastcisier may be selected from sorbitol, glycerol or mixtures thereof such as a mixture of sorbitol and glyercol in the respective weight ratio of 60:40 by weight of solids.
- the films of the present invention may have one or more of the following benefits as wound dressings.
- the films have a reduced tendency to wrinkle which leads to less blood pockets being formed under the skin and therefore a reduction in the pain felt by the patient.
- the films are sufficiently porous to water (and optionally oxygen) yet may maintain a moist wound environment and/or allow exudate to evaporate from the wound in a controlled way to aid wound healing, whilst excluding substantially all micro-organisms from the wound.
- the film is able to adapt its WVTR to the amount of fluid present underneath the dressing. Due to this intelligent water vapor handling property a substantially ideal moist wound environment is maintained and cell growth can be at a maximal rate.
- the films have a reduced tendency to slip on a moist wound and therefore are easier to locate adjacent the wound.
- micro-rough surface of the film is also believed to assist in cell adhesion which may promote skin re-growth and/or wound healing.
- An increase in the rate of wound healing leads to a reduced hospitalisation with resultant benefits to patients and cost reductions to the health care provider. Wounds can heal with substantially less scarring.
- the film is made by a non-microbiological method (for example regenerated cellulose film ) standard equipment used to produce such cellulose can be used to readily prepare the film in large volumes.
- a non-microbiological method for example regenerated cellulose film
- the film is easy to handle because it is relatively stiff when dry and yet becomes pliable and/or elastic after wetting which enables easy draping on the wound. Furthermore handling is also good because of the mechanical stability of the material.
- the film is inert, lint free and may be readily sterilised.
- the film can be applied as a one piece film obviating the need for a more complicated dressing.
- the physical properties of the film allow it better to conform to the body surface.
- the film is easily stored and has a long shelf life.
- the strong adhesion of the film to the wound reduces the proliferation of germs, and leaves the wound hermetically sealed.
- the film can be made with good optical properties (i.e. transparent) which allows visual inspection of the wound without removal of the dressing and thus the pain to the patient and risk of infection of the wound is reduced.
- the film can be applied once and the dressing does not need to be changed.
- the film can be applied delicately over the injured region and because of the optimised surface roughness it can be readily but rapidly positioned adjacent the wound with a much reduced tendency to form air bubbles or blood secretions between the wound and the film.
- the film quickly absorbs exudate from the wound and this process is enhanced because of the increased film surface area due to the roughened surface.
- the film allows the exudate to coagulate within the film and thus form a bridge between the film and the wound. Coagulation can also occur before the exudate has penetrated the film, for example both in the microscopic spaces existing between the particles on the film and on the wound surface.
- this improved adhesion prevents hydro-electrolytic losses and substantially reduces the risk of infection.
- the film therefore, makes it possible for the epithelial tissues to regrow since the wound is isolated and contamination is avoided. There is no necessity to change dressings, since the adhesion of the film to the wound will only cease gradually, as the tissue regenerates.
- the particulate material is cellulose (such as cellulose fibers and/or ground cellulose) then the film may be formed totally from inert cellulose which does not have any undesired medicinal action on the wound. Once the wound heals under these optimum conditions, the film ceases to adhere to the patient, and leaves no residue on the regenerated area.
- the cellulose film Since the cellulose film is strong and inert, it can be sterilised in any convenient way. It may be stored at any temperature, and does not require special conditions.
- the film has determined permeability to liquids and air, a characteristic molecular weight and structure, a predictable thickness when dehydrated, in addition to other specific physical characteristics.
- the cellulosic film may be produced by any conventional non-microbiological means.
- a preferred cellulosic film is produced by regeneration of natural cellulose from any source using the well known viscose process. More preferably the cellulose source comprises mostly or substantially wood, such as a wood pulp.
- the cellulosic film may include other conventional film additives and/or coatings well known in the art of film making and which are compatible with wound dressing, such as softeners, anti-static agents, adhesive coatings and/or may be tinted or otherwise treated, for example impregnated with one or more pharmaceutically active ingredients.
- the film may also comprise other layers and/or be a laminate.
- the particulate material is itself any natural fiber (such as cellulosic fiber, wool pulp, cotton linters, vegetable fiber, hemp and/or sisial), synthetic fiber (such as viscose, polyester, and/or nylon) and/or particles of any shape such as spherical and/or amorphous particles (e.g. ground cellulose, cellulose spheres, amorphous polysaccharides, starch, chitin, super absorbent polyacrylate powder and/or silver zinc zeolite particles).
- the particulate material comprises cellulosic particles, such as cellulose fibers.
- the cellulose fibers may be substantially from a wood source, for example at least 90% from a wood source.
- the cellulose fibers may also have a lignin content of at least 1 % by weight.
- the particulate material does not comprise non-wood cellulose fibers less than 2 mm in length.
- the particulate material may also comprise one or more of the following; cross-linked gelatin beads (such as those available commercially from KC Biological Co., USA. under the trade name Gell-Beads); charged group-added polyacrylamide beads (such as those available commercially from Bio-Rad Co., USA.
- Biocarrier under the trade name Biocarrier
- polystyrene beads such as those available commercially from Nunc Co., Denmark under the trade name Biosilon
- dextran beads such as those available commercially from Flow Labs Co., USA under the trade name Superbeads
- cellulose granules such as those available commercially from Whatman Co., UK under the trade designation DE-52
- collagen-coated dextran beads such as those available commercially from Pharmacia Upjohn, Sweden under the trade name Cytodex
- cellulose acetate hollow fibers such as those available commercially from Amicon Co., USA).
- the mean linear dimensions of the fibers are preferably from about 5 ⁇ m to about 5 mm, more preferably from about 15 ⁇ m to about 3 mm, most preferably from about 20 ⁇ m to about 1000 ⁇ m, for example from about 20 ⁇ m to about 100 ⁇ m, e.g. from about 20 ⁇ m to about 50 ⁇ m along a major axis (such as length), and from about 0.1 ⁇ m to about 100 ⁇ m, more preferably from about 5 ⁇ m to about 80 ⁇ m, most preferably from about 10 ⁇ m to about 50 ⁇ m, for example from about 10 ⁇ m to about 30 ⁇ m, e.g. from about 10 ⁇ m to about 20 ⁇ m, along a minor axis (such as fiber diameter or thickness) preferably orthogonal to the major axis.
- minor axis such as fiber diameter or thickness
- the average thickness of a film of the present invention may be up to about 2 mm (e.g. if a foamed film is used), preferably up to about 45 ⁇ m, before incorporation of the particulate additives. More preferably the average thickness of a film of the present invention is from about 20 to about 30 ⁇ m as this has been found to conform better with the contours of a wound.
- the film of the invention is provided in a form directly suitable for use in wound dressing, more preferably as a sterile and packaged form capable and effective for such a use, most preferably in a form which has obtained the necessary regulatory approval for use in such an application.
- the film of the present invention comprises a sheet-like substrate comprising cellulosic film modified with cellulosic beads and/or fibers and optionally may further comprise one or more pharmaceutically-effective active ingredients.
- the film of the present invention includes as a component thereof a regenerated cellulose membrane film which substantially excludes microbiological organisms when it is applied topically to a wound.
- a preferably sterile wound dressing comprising a cellulosic film of the present invention as described herein preferably the film being sealed inside a sterilised tamper evident pack and/or being associated with instructions for use of said film as a wound dressing.
- a wound dressing film of the present invention may act as a partial or complete substitute for and/or an aid to any of the following in wound dressing: aminotic membrane, animal skin (e.g. pig skin), artificial skin, conventional wound dressings [e.g. bandages, gauze, plasters and the like], human skin [e.g. normal healthy skin jn situ or that obtained from cadaver]; protecting material, skin graft [e.g. autogeneous, allogeneic and/or donor], synthetic skin and/or vulnerary cover. Such a product may promote regrowth of the epidermis and/or dermis and/or healing of the wound.
- aminotic membrane e.g. pig skin
- conventional wound dressings e.g. bandages, gauze, plasters and the like
- human skin e.g. normal healthy skin jn situ or that obtained from cadaver
- skin graft e.g. autogeneous, allogeneic and/or donor
- synthetic skin and/or vulnerary cover
- Preferred amounts of particles which can be incorporated into the fluid are those ranges given herein for the amounts of particles in the film. However it will also be appreciated that to achieve a given amount of particles in a film of the invention, it may be necessary to add a greater amount of the particles to the fluid in the above process to compensate for loss of particles during the process.
- any suitable methods of incorporation can be used such as injection or stirring of the particulate additives which can be incorporated into any cellulose film made by any regenerated method.
- a preferred method is the well known viscose method for preparing cellulose film in which case the particles are added to the viscose.
- the cellulose film of the invention may also be used as a surgical suture, given the necessary preparation, and presents a high knot strength but preferably such films are used to prepare a sterile dressing in a form suitable for application to a wound.
- the dressings of the present invention which comprise a film of the present invention are permeable and biologically inert.
- Dressings of the present invention may optionally be impregnated with one or more active ingredients, such as chemotherapeutic agents, medicinal agents and/or additives which may be fluid, preferably powder, cream or liquid.
- the dressings can contain topical anaesthetics such as butamben picrate, lidocaine hydrochloride, piperocaine hydrochloride and the like; bacteriostatic agents such as silver zinc zeolite particles, silver nitrate (0.5% solution), sulfa drugs, for example, 10% suspension of p-aminomethyl- benzene sulfonamide in a water dispersible cream, benzalkonium chloride and the like; antibiotics such as bacitracin, neomycin, aureomycin, tetracycline, penicillin, polymyxin, streptomycin, signemycin, erthromycin, oleandomycin, and the like; topical steroids such as prednisone, dexamethasone, hydrocortis
- the quantity of the aforementioned medicinal agents, chemotherapeutic agents or additives which can be incorporated into the dressings of the present invention will, of course, be dependent upon the particular agent, its solubility, and the presence of other additives. In general, however, the agents will be employed in a therapeutic amount. This can range from about, 0.0001% and lower, upwards to about 40% and higher by weight of the film.
- chemotherapeutic agents and/or medicaments can be added to the dressing which can be transported to the site of the wound by diffusion through the material.
- the dressings of the present invention may be used as wet or dry dressings in combination with an occlusive film backing for some applications.
- the dressing may provide a source of moisture over an extended period of time and ensure an antibacterial environment.
- a dressing of the present invention which is also impregnated with an aqueous solution containing an antimicrobial agent, may be applied to such an ulcer and covered with an occlusive film backing to prevent evaporation of moisture from the dressing.
- a wide variety of films are suitable for use as optional backings for a wound dressing of the present invention include, for example, polyvinylidene chloride, polyethylene, polypropylene, polyethylene terephthalate, polyamides, polyvinyl chloride, cellulose acetate and derivatives thereof, polydimethyl butadiene, polyurethanes, polyvinyl alcohol, silicone rubbers, polyacrylic acid, and the like.
- the backing film may be attached to the film of the invention through the use of adhesives, mechanical fastening and/or (e.g. if the film is impregnated with liquid) by surface tension of liquid.
- the backing film may extend beyond the area of the dressing and be adhesive coated to form an island dressing which may be secured directly to the skin of the patient.
- Such liquids may be intended specifically for use with burns to provide for evaporation from the dressing to provide a cooling effect over the wound area.
- Such dressings may comprise an evaporative liquid which may be water, saline or a water/glycerol or water/polyethylene glycol solution and are not covered with an occlusive backing film during use.
- the products of this invention may also be produced in long lengths for use as burn bandages, and in large sheets, i.e. 3 by 5 feet or greater, for use as burn blankets.
- Cold packs for burns may be provided with a removable insulating backing for an optionally liquid impregnated cellulosic film of the invention.
- Cold packs are chilled prior to application and do not initially depend upon evaporative cooling. The cooling effect of the cold pack may be extended by removing the backing and allowing evaporative cooling to take place.
- Cold packs additionally may utilise thicker or multiple layers of film of the invention optionally impregnated with liquid to increase their heat capacity.
- Dressings according to the present invention may also be used as long-term coverings for severe burns and certain other wounds.
- a thin dressing of this invention from about 0.1 ⁇ m to about 5 mm thick is placed immediately over the wound and a second dressing containing medicaments or other wound treating agents may be placed over the primary dressing. Since the medicaments will migrate through the primary dressing to the wound surface, the secondary dressing may be changed from time to time to renew the medicament treatment while the healing process of the wound is observed through the primary dressing which is not disturbed.
- the dressings of the present invention may comprise a single sheet of the cellulosic film prepared as described herein which may or may not be impregnated with liquid, such films may also contain other optionally reinforcing sterile materials such as random or carded fibers, plastic net, reticulated plastic film, open weave fabrics and fabric mesh which may be incorporated in the dressing if desired.
- sterile materials such as random or carded fibers, plastic net, reticulated plastic film, open weave fabrics and fabric mesh which may be incorporated in the dressing if desired.
- nylon gauze, rayon net, Dacron or cellulose mesh or reticulated polyethylene can be laminated with the cellulosic film.
- An additional optional feature of the dressings of the present invention is their ability to absorb fluid from the wound site when the dressing is applied.
- moisture evaporating from the dressing will tend to be replaced by fluids exuding from the burn site.
- a dressing is covered with an occlusive film to prevent the dressing from drying out while in place over the wound.
- the dressings of the present invention may be sterilised prior to use by any appropriate method such as auto-claving, irradiation with cobalt-60 and/or electron beam and/or ethylene oxide treatment.
- the dressings may be packaged in sterile hermetically sealed moisture-proof containers.
- the dressings may be heat sealed in packages constructed of aluminum foil laminated with a heat sealable polymeric film such as polyethylene.
- the contents of the package may be sterilised by irradiation in accordance with conventional methods for packaging surgical products. Sterile materials may be stored for extended periods of time with no adverse effect.
- the dressings of the present invention may be constructed in a variety of shapes, sizes, and thicknesses and be impregnated with a variety of physiologically-acceptable liquids and medicaments to accommodate the requirements of any particular application. Additionally, the films of the present invention materials may be used in combination with internal reinforcements or external backing films and may be used as the pad portion of island dressings which include adhesive attachment means.
- a sterile wound dressing of the present invention may comprise a cellulosic film of the present invention sealed inside a sterilised tamper evident pack and being associated with instructions for use of said film as a wound dressing.
- One aspect of the invention is the use of a dressing of the present invention in a method of protecting a wound.
- Another aspect of the invention is the use of a cellulosic film of the present invention, in a method of preparing a dressing of the present invention.
- Another aspect of the invention is a method of preparing a dressing of the present invention, comprising the steps of sterilising a cellulosic film of the present invention, and packing said film under sterile conditions.
- films of the present invention are primarily designed for use in the field of wound dressings they could be used in other applications where similar film properties are desired.
- a production machine was set up in a conventional manner to produce regenerated cellulose film from the well known xanthate viscose method.
- the viscose used had a cellulose content of 9.3% and the resultant film had a substance of 30 gm "2 .
- a 15% dispersion of highly pure cellulose fibers in water was prepared. These fibers were from a beech wood source and were milled to an average length of 23 ⁇ m with an average thickness of 17 ⁇ m. This dispersion was injected into the viscose stream just prior to the extrusion die and homogenised through a static (labyrinth) mixer before casting into a film. The flow rate of the dispersion was adjusted to produce a level of 5% by weight of fibers (as a percentage of the regenerated cellulose content) in the final film, which had a substance of 30 gm "2 .
- the film was plasticised with a mixture of sorbitol and glycerol (60:40 by weight solids) at a level of 20% of the regenerated cellulose content, dried and wound into reels.
- Example 2 had some wrinkles and pools, some curling.
- Example 3 had curling which straightened, no pools.
- Example 4 had no wrinkles or pools.
- Films prepared in accordance with the Examples 1 to 4 described herein are of particular use in preparing dressings for application to a wound formed by an autograft on a burns patient.
- a dressing of the present invention comprising a film exemplified in Examples 1 to 4 can be applied, after bleeding has stopped, directly to the donor site such that no air bubbles or blood secretions are formed between the dressing and the wound. Due to its good wettability the dressing adheres very rapidly and firmly to the moist wound surface. The rough surface of the dressing ensures that it is not displaced. Once the dressing is applied to and completely covers the wound, it completely seals the wound, forming a mechanically stable protective layer. This protects nerve endings thus eliminating pain.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Manufacturing & Machinery (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0013186 | 2000-06-01 | ||
GBGB0013186.2A GB0013186D0 (en) | 2000-06-01 | 2000-06-01 | Wound dressings |
PCT/EP2001/006194 WO2001091681A1 (en) | 2000-06-01 | 2001-05-31 | Wound dressing |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1289457A1 true EP1289457A1 (en) | 2003-03-12 |
Family
ID=9892683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01955296A Withdrawn EP1289457A1 (en) | 2000-06-01 | 2001-05-31 | Wound dressing |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1289457A1 (en) |
AU (1) | AU2001277498A1 (en) |
CA (1) | CA2411240A1 (en) |
GB (1) | GB0013186D0 (en) |
WO (1) | WO2001091681A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6870074B2 (en) * | 2002-05-23 | 2005-03-22 | Hollister Incorporated | Thin film scar dressing and use thereof |
GB0300625D0 (en) | 2003-01-10 | 2003-02-12 | Bristol Myers Squibb Co | Wound dressing |
WO2004110323A1 (en) * | 2003-06-02 | 2004-12-23 | Beatrice Pfister | Dressing |
WO2007113452A1 (en) * | 2004-10-22 | 2007-10-11 | First Water Limited | Absorbent materials and articles |
CN101862470A (en) * | 2010-05-28 | 2010-10-20 | 武汉锐尔生物科技有限公司 | Bacteriostatic hydrocolloid dressing and preparation method thereof |
GB202202788D0 (en) * | 2022-03-01 | 2022-04-13 | Smith & Nephew | Oxygen delivery to a wound |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB942305A (en) * | 1958-12-23 | 1963-11-20 | Parachem Corp | Improvements in or relating to antiseptic film and method and apparatus for producing the same |
US3426754A (en) * | 1964-06-12 | 1969-02-11 | Celanese Corp | Breathable medical dressing |
US3505045A (en) * | 1968-03-19 | 1970-04-07 | Minnesota Mining & Mfg | Abrasive backings saturated with copolymers of acrylic ester and nitrile monomers |
FR2040768A5 (en) * | 1969-04-11 | 1971-01-22 | Panatlantic Corp | Cloth impregnated with treatment fluid - contained in micro capsules |
US4373519A (en) * | 1981-06-26 | 1983-02-15 | Minnesota Mining And Manufacturing Company | Composite wound dressing |
AU562370B2 (en) * | 1982-10-02 | 1987-06-11 | Smith & Nephew Associated Companies Plc | Moisture vapour permeable adhesive surgical dressing |
US4990339A (en) * | 1987-11-16 | 1991-02-05 | H. B. Fuller Company | Dermal treatment film |
EP0386960A3 (en) * | 1989-03-07 | 1991-10-23 | American Cyanamid Company | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings |
US5393528A (en) * | 1992-05-07 | 1995-02-28 | Staab; Robert J. | Dissolvable device for contraception or delivery of medication |
AU6507494A (en) * | 1993-04-13 | 1994-11-08 | Nicholas John Mills | Thermal coverings/wound dressings |
WO1995003018A1 (en) * | 1993-07-21 | 1995-02-02 | Smith & Nephew Plc | Surgical dressing |
-
2000
- 2000-06-01 GB GBGB0013186.2A patent/GB0013186D0/en not_active Ceased
-
2001
- 2001-05-31 WO PCT/EP2001/006194 patent/WO2001091681A1/en not_active Application Discontinuation
- 2001-05-31 CA CA002411240A patent/CA2411240A1/en not_active Abandoned
- 2001-05-31 AU AU2001277498A patent/AU2001277498A1/en not_active Abandoned
- 2001-05-31 EP EP01955296A patent/EP1289457A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0191681A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2411240A1 (en) | 2001-12-06 |
WO2001091681A1 (en) | 2001-12-06 |
GB0013186D0 (en) | 2000-07-19 |
AU2001277498A1 (en) | 2001-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4588400A (en) | Liquid loaded pad for medical applications | |
US4788146A (en) | Liquid loaded pad for medical applications | |
JP2641428B2 (en) | Microbial polysaccharide product and method for producing the same | |
US5653699A (en) | Spyrosorbent wound dressings for exudate management | |
EP1356831B1 (en) | Microbial cellulose wound dressing for treating chronic wounds | |
EP1473047A1 (en) | Microbial cellulose wound dressing, containing PHMB, for treating chronic wounds | |
US20110218472A1 (en) | Non drug based wound dressing polymer film and a method of producing the same | |
JPH0260338B2 (en) | ||
RU2437681C1 (en) | Wound covering with therapeutic action | |
JP6290184B2 (en) | Wound dressing | |
Thomas | A review of the physical, biological and clinical properties of a bacterial cellulose wound | |
JP4486304B2 (en) | Microbial cellulosic wound dressings for the treatment of chronic wounds | |
EP1289457A1 (en) | Wound dressing | |
JPH04303445A (en) | Wound covering material | |
EP1297059A1 (en) | Films and uses thereof | |
CN219184532U (en) | Chitosan antibacterial dressing | |
KR100372560B1 (en) | Charcoal filled hydrogels dressings and process for preparing thereof by irradiation | |
CN207047481U (en) | A kind of medical supplies preparation facilities | |
CA1295327C (en) | Pliant, water-absorbent, laminar mass of microbial cellulose | |
CN114699549A (en) | Chitin antibacterial hemostatic material film and preparation method thereof | |
Alves et al. | Nano-bioabsorbent composite wound dressing for exudate management |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030102 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VON DER WETH, ANDREAS, MATTHIAS Inventor name: RUHNAU, KLAUS, ALFRED Inventor name: ACHTERBERG, VOLKER, FRITZ Inventor name: MARSHALL, COLIN,"SEBASTIAN" |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INNOVIA FILMS LIMITED |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20071201 |